Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry

Professor Magdi Yaqoob

Joint Head of Department

Centre: Translational Medicine and Therapeutics

Email: m.m.yaqoob@qmul.ac.uk
Telephone: +44(0) 20 7882 2121

Profile

Magdi Yaqoob is Professor of Nephrology within Centre for Translational Medicine & Therapeutics at the William Harvey Research Institute (WHRI) and academic director of department of Renal Medicine and Transplantation at the Barts Health NHS Trust, UK. He graduated as one of the best graduates in Medicine (1982) from Dow Medical College, Karachi University, Pakistan. After general professional clinical training during which he obtained membership of the Royal College of Physician London (1985) he started specialist nephrology training in Liverpool, UK in 1987. He submitted his MD thesis on occupational factors in kidney disease in Liverpool University 1993. He obtained NIH fellowship to work as postdoctoral clinician/scientist under Prof Robert Schrier at Denver Colorado (194-1995).  He joined the Royal London Hospital as consultant in 1996 and was awarded personal chair in Nephrology by QMUL in 2011. He received several awards (best European young investigator of the year 1992 and trainee investigator of the year by association of physicians USA, 1994). 

Magdi Yaqoob is an internationally recognised expert in nephrology and transplant medicine in area of cardiovascular diseases of uraemia, renal anaemia, and renal bone disease, progression of chronic kidney disease and mediators of acute kidney injury.

Research

Nephrology and Transplant Medicine Research Group

We have a long-standing research interest in the pathophysiology and novel therapeutic strategies (preclinical and clinical) of:

  1. Ischaemia-reperfusion of the heart in uraemia and kidney (acute kidney injury, chronic kidney disease, renal fibrosis)
  2. Genetic factors determining the long-term outcomes of renal transplants
  3. Insulin resistance in CKD
  4. Autophagy and premature ageing in uraemia
  5. Molecular mechanisms of EPO resistance.

Over the years, we have identified a number of new therapeutic targets poly (ADP-ribose) polymerase (PARP), Hypoxiainducible factor stabilizers, calpain/caspases, acidosis, anti-inflammatory suppression of cytokine signalling, pleiotropic effects of erythropoietin their analogues, ischaemic preconditioning, sodium sensing in endothelial cells and galectins 1 & 3 in microcirculatory unit to name but a few. More recently as part of the NIHR-funded Barts-BRU, we have focused on the development of highly translational repositioning strategies, the efficacy of which is currently evaluated in patients with chronic kidney disease and transplant waiting list patient.

Publications

View Profile Publication Page

Collaborators

Internal

  • Prof Chris Thiemermann (WHRI)
  • Prof Mauro Perretti (WHRI)
  • Prof Amrita Ahluwalia (WHRI)
  • Prof Chris Thiemermann (WHRI)
  • Prof Roger Corder (WHRI)
  • Prof Tim Warner (WHRI)

External

  • Prof Anthony Cerami (University of Leiden, The Netherlands)
  • Dr Massimo Collino (University of Turin, Italy)
  • Prof Jonathan Sekl (Edinburgh University)
  • Prof Derek Gilroy (UCH)
  • Dr Andrew Wragg (Barthealth NHS UK)
Back to top